ライフサイエンスコーパス: dyslipidemic

1 e similar risk to individuals who were never dyslipidemic.

2 ats, were obese (621 vs. 461 g; P < 0.0001), dyslipidemic (133 vs. 67 mg/dl; P < 0.001), and glucose

3 ipid levels were determined at enrollment in dyslipidemic adult patients on stable lipid-lowering the

4 Dyslipidemic and inflammatory environments attenuate end

5 s, i.e. inhibition of caspase-1 in ECs under dyslipidemic and inflammatory environments attenuates EC

6 Under these dyslipidemic and inflammatory environments, EC-caspase-1

7 development of hypertensive complications in dyslipidemic and/or insulin-resistant patients.

8 pensable for NAMPT insulin-sensitizing, anti-dyslipidemic, and light-cycle thermogenic effects.

9 Peritoneal macrophages from dyslipidemic animals were primed for more robust TLR res

10 ese HXO mice became as insulin resistant and dyslipidemic as obese FLX mice.

11 ke of L5, an electronegative LDL abundant in dyslipidemic but not normolipidemic human plasma.

12 Mean HDL cholesterol levels are lower in dyslipidemic children from households with smokers than

13 ians screening for dyslipidemia or following dyslipidemic children should be aware of the powerful ef

14 The clinical use of niacin to treat dyslipidemic conditions is limited by noxious side effec

15 between positive selection and the obese and dyslipidemic conditions.

16 put and hypertension) or metabolic (that is, dyslipidemic) derangements associated with obesity may p

17 n APOA5, elevated plasma triacylglycerol and dyslipidemic disease.

18 promotes unregulated platelet activation in dyslipidemic disorders.

19 tic CB1 receptor resulted in a rescue of the dyslipidemic effects of glucocorticoid exposure, while n

20 etary and pharmaceutical manipulation of its dyslipidemic effects.

21 th region-wide significance for low HDL-C in dyslipidemic families of Mexican and European descent an

22 ance, we tested this gene for association in dyslipidemic families originating from two distinct popu

23 trait in 2 multigenerational French Canadian dyslipidemic families.

24 entral fat mass (Delta+40 g), accompanied by dyslipidemic (>30% elevated, P < 0.05) serum triglycerid

25 demic-high triglycerides (182 participants), dyslipidemic-high FFA (234 participants), and insulin re

26 c (relative risk, 8.7; 95% CI, 2.7-27.8) and dyslipidemic-high FFA (relative risk, 3.4; 95% CI, 1.0-1

27 subgroup, women in the IR-hyperglycemic and dyslipidemic-high FFA subgroups had offspring with 4.27%

28 articipants), high HDL-C (355 participants), dyslipidemic-high triglycerides (182 participants), dysl

29 sequences of these genes were analyzed in 80 dyslipidemic individuals.

30 The term 'HIV/HAART associated dyslipidemic lipodystrophy (HADL)' describes this syndro

31 e effects of diabetes are masked in severely dyslipidemic mice, suggesting that the effects of glucos

32 shown to inhibit atherosclerosis in several dyslipidemic mouse models.

33 Individuals who had dyslipidemic non-HDL-C in childhood but whose non-HDL-C

34 reased risk of CVD events, but those in whom dyslipidemic non-HDL-C levels resolve by adulthood have

35 elihood of an individual having at least one dyslipidemic parent reveals an OR = 6.94 (CI 5.28-9.30)

36 5.28-9.30) compared to those who do not have dyslipidemic parents.

37 017 through July 2018), abdominally obese or dyslipidemic participants in Israel were randomly assign

38 sed) weight-loss trial, abdominally obese or dyslipidemic participants in Israel were randomly assign

39 Abdominally obese/dyslipidemic participants were randomly assigned to foll

40 roved continuity of care for newly-diagnosed dyslipidemic patients might reduce the risk of atheroscl

41 ain levels and may be a treatment option for dyslipidemic patients who cannot tolerate statin therapy

42 istration with other lipid-altering drugs in dyslipidemic patients, including a large (n=2121) 96-wee

43 than either the general population or non-FH dyslipidemic patients.

44 s surrogate endpoints for clinical trials in dyslipidemic patients.

45 ffspring with prenatal famine exposure had a dyslipidemic pattern characterized by elevated total cho

46 Features of the dyslipidemic pattern reported with the use of antiretrov

47 older, overweight or obese, hypertensive, or dyslipidemic people.

48 of n-3 HUFAs in the diet of hypertensive and dyslipidemic persons may have substantial benefits in re

49 fe and significantly reduced lipid levels in dyslipidemic PLHIV on maximally-tolerated statin therapy

50 ate the efficacy and safety of evolocumab in dyslipidemic PLHIV.

51 of twelve DS samples (75%) clustered into a dyslipidemic profile (cluster 1), compared to 209 of 513

52 studies have suggested that there is a novel dyslipidemic profile consisting of isolated low high-den

53 patibility complex-mismatched, diabetic, and dyslipidemic rats, immunologic and metabolic mechanisms

54 d hepatic lipids when orally administered to dyslipidemic rodent models.

55 as been shown to be effective in attenuating dyslipidemic states.

56 ecretory degradation may be relevant in some dyslipidemic states.

57 cell disease (SCD) patients often exhibit a dyslipidemic sub-phenotype.

58 added to LDL-C-lowering therapy, but a small dyslipidemic subgroup may benefit.

59 Dyslipidemic subjects produced TGRL that increased endot

60 We conclude the altered metabolism in dyslipidemic subjects produces TGRL with a unique oxylip

61 mized, observer-blinded study, we treated 60 dyslipidemic subjects without cardiovascular disease wit

62 al fluency, particularly in hypertensive and dyslipidemic subjects.

63 can Caribbeans were less centrally obese and dyslipidemic than Europeans.

64 Among available dyslipidemic therapies, although statins remain the main

65 Combination dyslipidemic therapy affords the most efficacious approa

66 The importance of combination dyslipidemic therapy, such as a statin plus niacin, in t

67 was reduced to optimal levels with intensive dyslipidemic therapy.

68 a large proportion of psoriatic patients are dyslipidemic, this finding is of clinical significance a

69 ead of a new class of drugs for treatment of dyslipidemic type 2 diabetes.

70 ely insulin resistant, hyperinsulinemic, and dyslipidemic, with evidence of endothelial dysfunction,